Envista (NYSE:NVST) releases quarterly earnings results, beats expectations by $0.04 EPS. Posted by Andrew Walz on Nov 4th, 2026 Envista (NYSE:NVST - Get Free Report) issued its earnings results on Wednesday. The company reported $0.40 EPS for the quarter, topping the consensus estimate of $0.36 by $0.04, FiscalAI reports. Envista had a net margin of 3.33% and a return on equity of 7.88%. The company had revenue of $691.50 million for the quarter, compared to analyst estimates of $688.74 million. During the same period in the previous year, the firm earned $0.32 EPS. The business's revenue was up 3.2% on a year-over-year basis. Here are the key takeaways from Envista's conference call: * Envista reported 2.7% core sales growth, with adjusted EBITDA up 9% and adjusted EPS up 25%; gross and EBITDA margins expanded 20 and 80 basis points, respectively. Free cash flow conversion was 97%, and net leverage remained low at 0.6x. * The company raised its 2026 outlook, now expecting 3.75%-4.25% core sales growth, 12.5%-14% adjusted EBITDA growth, and adjusted EPS of $1.54-$1.58. Management said the fourth-quarter outlook implies slightly negative core growth, partly reflecting four fewer selling days and continued macro uncertainty. * China sales fell at a low-double-digit rate as orthodontics customers destocked ahead of VBP; management expects the process to bring substantial price reductions, including about 50% for orthodontics and 10%-15% for implants. It expects VBP to support volume and share gains, but acknowledged margin pressure in China. * Spark grew at a high-single-digit rate, diagnostics and implants each grew mid-single digits, and Envista said it continued to gain share in diagnostics. Management highlighted a strong new-product pipeline and said broader commercialization of recent launches will be a key growth priority for 2027. Envista price performance. NVST stock traded up $2.44 on Wednesday, reaching $27.21. The company had a trading volume of 6,113,924 shares, compared to its average volume of 3,135,394. Envista has a 1 year low of $18.77 and a 1 year high of $30.42. The company has a debt-to-equity ratio of 0.47, a quick ratio of 2.07 and a current ratio of 2.43. The company's fifty day moving average is $24.49 and its 200 day moving average is $25.74. The company has a market cap of $4.37 billion, a P/E ratio of 46.91, a PEG ratio of 1.26 and a beta of 0.94. Analyst ratings changes. NVST has been the subject of several recent analyst reports. JPMorgan Chase & Co. upgraded shares of Envista from a "neutral" rating to an "overweight" rating and raised their price objective for the company from $29.00 to $32.00 in a research note on Thursday, September 3rd. Deutsche Bank Aktiengesellschaft set a $32.00 target price on shares of Envista in a research report on Thursday, September 3rd. Morgan Stanley set a $23.00 target price on shares of Envista in a research report on Thursday, August 6th. Leerink Partners dropped their target price on shares of Envista from $35.00 to $32.00 and set an "outperform" rating for the company in a report on Wednesday, October 14th. Finally, Weiss Ratings upgraded shares of Envista from a "hold (c-)" rating to a "hold (c)" rating in a research report on Thursday, August 6th. Six equities research analysts have rated the stock with a Buy rating and eleven have issued a Hold rating to the company's stock. According to data from MarketBeat.com, the company presently has an average rating of "Hold" and an average price target of $28.86. Insiders place their bets. In other Envista news, SVP Mischa Reis sold 8,000 shares of the firm's stock in a transaction on Thursday, August 20th. The stock was sold at an average price of $27.50, for a total transaction of $220,000.00. Following the completion of the transaction, the senior vice president owned 27,321 shares of the company's stock, valued at approximately $751,327.50. This trade represents a 22.65% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 0.99% of the company's stock. Envista company profile. Envista Holdings Corporation (NYSE: NVST) is a global dental products and technologies company headquartered in Brea, California. The company develops, manufactures and markets products used by dentists, dental specialists, dental laboratories and other oral health professionals. Envista's portfolio includes dental implants, orthodontic systems, digital imaging and workflow solutions, dental consumables, treatment equipment and related technologies. Its brands include Nobel Biocare, Ormco, DEXIS and Kerr, which provide products and services spanning implant dentistry, orthodontics, diagnostic imaging, restorative care and general dental practice management. Envista was established as an independent public company in 2019 following its separation from Danaher Corporation. Receive News & Ratings for Envista Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Envista and related companies with MarketBeat.com's FREE daily email newsletter.

Envista to move HQ from Brea to Irvine. October 26, 2026 Envista Holdings Corp. is ending a decade in Brea, with plans to move its headquarters to Irvine by 2028 - a move prompted by the planned demolition and redevelopment of its current home. The dental products maker, Brea's most valuable public company with a valuation near $3.8 billion (NYSE: NVST), has signed three separate leases totaling more than 120,000-square feet at Lakeview Business Center, owned by Newport Beach-based Irvine Company, according to CoStar data. "We've loved our time in Brea and are excited to begin our next chapter in Irvine in 2028. Our new headquarters is an investment in our future and in our people, creating a modern environment designed to help employees collaborate, innovate and build rewarding careers." -Chief Financial Officer Eric Hammes The move comes as the 97,000-square-foot building Envista occupies in Brea faces a major transformation. Its current headquarters is located on part of the 34-acre Beckman Coulter campus, which local developer Dwight Manley purchased for $140 million in January. The campus is slated to be torn down and redeveloped into single-family homes and the first-ever Costco for the area. Envista was spun out of Danaher Corp., a global conglomerate with segments in life sciences, diagnostics and biotechnology, in 2018 and went public the following year. Danaher acquired Brea-based laboratory and diagnostic equipment maker Beckman Coulter for approximately $6.8 billion in 2011. Over the summer, Washington, D.C.-based Danaher closed on its $9.9 billion buyout of Irvine-based Masimo Corp. One of Biggest Office Deals of the Year The three leases combined represent the second-largest new office deal in Orange County this year. The Business Journal was first to report last month on Taco Bell and Habit Burger & Grill's lease for a 254,000-square-foot, three-building campus on Alton Parkway in Irvine, which the two restaurant chains plan to relocate to by spring 2028. Both deals highlight continued demand for large office campuses in Irvine as Orange County's office market shows gradual signs of stabilizing. CBRE reported vacancy rates slightly increased to 13.3% in the second quarter, while availability fell to 18%, down from the adjusted rate of 19.5% in the first quarter. Envista Takes Over Former Bollinger Facility Lakeview Business Center is a 17-building campus located a short walk from the Bass Pro Shops store in the Irvine Spectrum. Amenities include seven outdoor collaboration and event spaces, barbecues and onsite auto detailing services. Envista's new headquarters will span three adjacent buildings at 100 Technology Drive and 15360 and 15370 Barranca Parkway, one of which used to be occupied by Brea-based Bollinger Innovations, formerly known as Mullen Automotive. The struggling electric vehicle maker, which has undergone numerous reverse stock splits and transitioned from the Nasdaq to Over the Counter after its market cap fell below $50,000, opened an EV development center at 100 Technology Drive in 2022. CoStar data shows that Bollinger moved out of the 31,602-square-feet facility last December, leaving the entire building vacant. Job Listings Point to 2028 Q1 Move While Envista has not officially announced the move, job postings for manufacturing and engineering positions say the company will relocate its office from Brea to Irvine in the first quarter of 2028. Envista in August reported 537 local employees, making it the fourth largest dental company in Orange County by headcount. Companywide, it counts more than 12,000. Envista owns more than 30 dental brands, including Ormco and Nobel Biocare, that are used in 200 million dental procedures a year, according to its website. In 2025, Envista reported a revenue increase of 8% to $3 billion. The company posted second quarter earnings in August with revenue of $731 million, surpassing the $716.3 million expected by analysts. Management also raised sales growth guidance to 3.5% to 4.5%, up from its prior range of 2% to 4%. "The dental market continued to show its characteristic resilience as patient demand for dental care remained stable despite macro pressure." -Chief Executive Paul Keel Envista continued to invest in product innovation with two new launches within its consumables business during the second quarter. The ZenSeal Pro is an all-in-one bioceramic endodontic sealer, used to close gaps between filling material and the canal wall in root canal procedures. The other product, the DemiPro, is a lightweight cordless curing light for restorative dental procedures. Move is another blow to Brea's office market BREA - The expected departure of Envista Holdings Corp. to Irvine in 2028 marks another big blow to Brea's base of office jobs. The city earlier this year saw developers buy the longtime campus of Beckman Coulter, with plans to replace the five-building campus that at its peak held close to 1,000 positions with a new housing development. Similarly, the multi-building office campus that held the base for Mercury Insurance, which employed nearly 1,600 pre-pandemic, in 2024 was sold to developer Dwight Manley for $31.5 million with an eye toward residential development. Manley later sold the 9.7-acre site to Hearthstone Inc., a division of Lennar Homes, for $45 million. The Brea City Council approved Lennar Homes' proposal to redevelop the site into a residential development with 179 attached units. Envista's new landlord, the Irvine Co., last year brought another big Brea business to the Spectrum area of the city, when food supplier Young's Market relocated its base to Spectrum Terrace. Envista currently employs 537 at its Brea base. Article sourced by OCBJ and writer Yuika Yoshida. Executive Editor Nancy Luna, Community Editor Mark Mueller and Real Estate Reporter Joseph Pimentel contributed to this report.

Chairs, handpieces, and sterilizers: the unsung heroes of the dental equipment market. Dentistry is changing quickly. Clinics that relied on analog tools now run digital scanners, laser systems, and connected treatment units. This post covers how the dental equipment market is structured, what is pushing it forward and holding it back, and where it is headed through 2033. Core Market Framework Dental equipment covers the instruments and systems used to examine, manipulate, treat, and restore oral disorders. Grand View Research segments the dental equipment market by product and region. By product: * Dental radiology equipment: intraoral and extraoral imaging, including digital X-ray units and sensors * Dental lasers: diode, carbon dioxide, and YAG lasers * Systems & parts: instrument delivery systems, vacuums and compressors, CBCT systems, CAD/CAM, furnaces, and electrosurgical equipment * Laboratory machines: ceramic furnaces, hydraulic presses, electronic waxers, and similar tools * Hygiene maintenance devices: sterilizers, air purification systems, and needle incinerators * Other equipment: chairs, handpieces, light-cure units, and scaling units By region: North America, Europe, Asia Pacific, Latin America, and Middle East & Africa, with country-level coverage across more than 20 markets. The competitive landscape has two tiers. Established players such as Dentsply Sirona, Planmeca, A-dec, Straumann, Envista, and 3M compete on broad portfolios, large installed bases, and heavy R&D spending. Emerging players such as AMD Lasers, Zolar Technology, and GIGAAMEDICAL compete on price, niche products, and regional distribution, mostly targeting small and mid-sized clinics. Discover more Read Daily News Hire PR Firms Go Deeper. Need the data behind these numbers? Get a look at the report's market estimates, trend analysis, and forecasts. Download Free Sample Report Strategic Drivers & Impeding Mechanics What's driving growth * A rising burden of oral disease. Oral diseases affect an estimated 3.9 billion people worldwide, according to the FDI World Dental Federation. Untreated tooth decay is the most prevalent condition in the Global Burden of Disease Study. Diets high in sugar, tobacco and alcohol use, and poor hygiene keep caries and periodontal disease widespread. More patients need diagnosis and treatment, so clinics and hospitals need more chairs, imaging systems, scanners, sterilization units, and lasers. * An aging population. By 2050, about one in six people globally will be over 65, up from one in eleven in 2019. That is roughly 1.5 billion people, and older patients have a higher need for restorative and surgical dental care. * Digital dentistry. Intraoral scanners, CAD/CAM systems, 3D printers, digital radiography, and cloud-connected practice software are becoming standard. They support same-day restorations, cut manual errors, and improve diagnostic accuracy and the patient experience. * Policy, awareness, and medical tourism. Public oral health programs, preventive care campaigns, and expanding clinic networks all lift demand. Dental medical tourism adds to it, especially in Asia, where patients are drawn by shorter waits, lower costs, and skilled practitioners. What's holding it back The high cost of imaging equipment. CBCT scanners, panoramic X-ray systems, cephalometric units, and digital radiography systems require large upfront investment. Beyond the purchase price, practices also pay for installation, software licensing, maintenance, calibration, radiation safety compliance, and staff training. For small and independent practices, that total cost can delay adoption or push them toward cheaper alternatives. The pandemic also left a mark. Clinic closures, PPE shortages, and the need to invest in new safety protocols strained many practices, although the market recovered once clinics reopened. Discover more Scale Logistics Need it tailored to your business? Add countries or segments, align the report to your product definitions, or go deeper on competitors, with up to 20% free customization. Customize This Report Market Overview & Growth Trajectory The global dental equipment market was valued at USD 12.5 billion in 2025 and is estimated at USD 13.2 billion in 2026. It is projected to reach USD 20.9 billion by 2033, growing at a CAGR of 6.8% from 2026 to 2033. Products. Systems & parts led in 2025 with a 40.4% revenue share, since these are the core tools behind almost every procedure. Dental lasers are the fastest-growing segment, with a projected CAGR of 9.2%. They are increasingly used in surgery, gum reshaping, and teeth whitening, and they offer controlled blood loss and less need for sutures. Regions. North America held the leading position in 2025 with a 38.6% share and is expected to grow at a 7.0% CAGR. The U.S. anchors the region thanks to strong infrastructure, established reimbursement policies, and a concentration of key players. Asia Pacific is the fastest-growing region at a 7.5% CAGR, helped by supportive government policies, a rising geriatric population, growing procedure demand, and strong medical tourism in China, Japan, and India. What it means for stakeholders. Success will likely go to companies that offer integrated digital ecosystems rather than standalone devices. That means diagnostics, imaging, treatment, and software working together, backed by clinical support, strategic partnerships, and strong distribution. Expansion through partnerships and acquisitions in emerging regions is also a clear competitive pattern. Explore our dedicated business services: Prism AI: Market Intelligence with Cited Research- Ask questions in plain language and get insights drawn from Grand View Research's entire research library, with sources cited. Create your free account today. U.S. Healthcare Facility Mapping & Intelligence Platform: Get facility-level intelligence to guide smarter decisions. Sign up Today Matched content.